21/08/2024 | Press release | Distributed by Public on 21/08/2024 19:47
August 21, 2024 | Registration Statement Nos. 333-270004 and 333-270004-01; Rule 424(b)(3) |
JPMorgan Chase Financial Company LLC
Structured Investments
Auto Callable Contingent Interest Notes Linked to the Common Stock of DexCom, Inc. due August 5, 2026
Fully and Unconditionally Guaranteed by JPMorgan Chase & Co.
Notwithstanding anything to the contrary set forth in the pricing supplement dated July 31, 2024, related to the notes referred to above (the "pricing supplement"), the Initial Value, the Interest Barrier and the Trigger Value are as set forth below:
Initial Value:The closing price of one share of the Reference Stock on the Pricing Date, which was $67.82
Interest Barrier / Trigger Value: 50.00% of the Initial Value, which is $33.91
CUSIP: 48135P4C2
Investing in the notes involves a number of risks. See "Risk Factors" beginning on page S-2 of the accompanying prospectus supplement, Annex A to the accompanying prospectus addendum, "Risk Factors" beginning on page PS-11 of the accompanying product supplement and "Selected Risk Considerations" beginning on page PS-4 of the pricing supplement.
Neither the Securities and Exchange Commission (the "SEC") nor any state securities commission has approved or disapproved of the notes or passed upon the accuracy or the adequacy of this amendment, the pricing supplement or the accompanying product supplement, prospectus supplement, prospectus and prospectus addendum. Any representation to the contrary is a criminal offense.
The notes are not bank deposits, are not insured by the Federal Deposit Insurance Corporation or any other governmental agency and are not obligations of, or guaranteed by, a bank.
You should read this amendment together with the pricing supplement and the related product supplement, prospectus supplement and prospectus and prospectus addendum, each of which can be accessed via the hyperlinks below. Please also see "Additional Terms Specific to the Notes" in the pricing supplement.
· Pricing supplement dated July 31, 2024:
http://www.sec.gov/Archives/edgar/data/1665650/000121390024064858/ea178739_424b2.htm
· Product supplement no. 4-I dated April 13, 2023:
http://www.sec.gov/Archives/edgar/data/19617/000121390023029539/ea152803_424b2.pdf
· Prospectus supplement and prospectus, each dated April 13, 2023:
http://www.sec.gov/Archives/edgar/data/19617/000095010323005751/crt_dp192097-424b2.pdf
· Prospectus addendum dated June 3, 2024:
http://www.sec.gov/Archives/edgar/data/1665650/000095010324007599/dp211753_424b3.htm
Amendment no. 1 to pricing supplement dated July 31, 2024 to product supplement no. 4-I dated April 13, 2023, the prospectus and prospectus supplement, each dated April 13, 2023, and the prospectus addendum dated June 3, 2024